Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure

Journal of the American College of Cardiology

Volumn 50, Issue 6, 2007, Pages 551-557

  Zacà, Valerio ^a   Rastogi, Sharad ^a   Imai, Makoto ^a   Wang, Mengjun ^a   Sharov, Victor G ^a   Jiang, Alice ^a   Goldstein, Sidney ^a   Sabbah, Hani N ^a  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; GELATINASE A; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOG; DRUG MEGADOSE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL; LONG TERM EXPOSURE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ANIMALS; CORONARY ANGIOGRAPHY; DOGS; FLUOROBENZENES; HEART FAILURE, CONGESTIVE; HEMATOPOIETIC STEM CELLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34547170021     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.050     Document Type: Article

References (34)

1. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
2. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
3. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 568-573
4. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F.
5. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients wih coronary artery disease. N Engl J Med 332 (1995) 481-487
6. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
7. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 (2001) 391-397
8. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
9. Vasa M., Fichtlsherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
10. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
11. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methilglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
12. Landmesser U., Engberding N., Bahlmann F.H., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
13. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
14. Sola S., Mir M.Q.S., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
15. Romuald W., Wilczek K., Nowalany-Kozielska E., et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97 (2006) 899-904
16. Jones P.H., Davidson M.H., Stein E.A., et al., STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 92 (2003) 152-160
17. Sabbah H.N., Stein P.D., Kono T., et al. A canine model of chronic heart failure produced by multiple sequential intracoronary microembolization. Am J Physiol 260 (1991) H1379-H1384
18. Sabbah H.N., Shimoyama H., Kono T., et al. Effect of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89 (1994) 2852-2859
19. Sabbah H.N., Stanley W.C., Sharov V.G., et al. Effect of dopamine β-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 102 (2000) 1990-1995
20. Kotton D.N., Summer R.S., Sun X., et al. Stem cell antigen-1 expression in pulmonary vascular endothelium. Am J Physiol 284 (2003) L990-L996
21. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
22. Li Y.Y., Feng Y.Q., Kadokami T., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci U S A 97 (2000) 12746-12751
23. Spinale F.G., Coker M.L., Bond B.R., and Zellner J.L. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46 (2000) 225-238
24. Ikeda U., Shimpo M., Ohki R., et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 36 (2000) 325-329
25. Morita H., Khanal S., Rastogi S., et al. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol 290 (2006) H2522-H2527
26. Liao J.K. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 52 (2004) 248-253
27. Laufs U., Kilter H., Konkol C., Wassmann S., Bohm M., and Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 53 (2002) 911-920
28. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (1999) 221-228
29. Orlic D., Kajstura J., Chimenti S., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98 (2001) 10344-10349
30. Kajstura J., Rota M., Whang B., et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 96 (2005) 127-137
31. van der Harst P., Voors A.A., van Gilst W.H., Böhm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71 (2006) 443-454
32. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 (2006) 338-341
33. Tavazzi L., Tognoni G., Franzosi M.G., et al., GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
34. Kjekshus J., Dunselman P., Blideskog M., et al., CORONA Study Group. A statin in the treatment of heart failure. Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069